Paschalis Vergidis1, Suzannah M Schmidt-Malan1, Jayawant N Mandrekar2, James M Steckelberg3, Robin Patel4. 1. Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, United States. 2. Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, United States. 3. Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, MN 55905, United States. 4. Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, United States; Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, MN 55905, United States. Electronic address: patel.robin@mayo.edu.
Abstract
OBJECTIVES: Implant-associated methicillin-resistant Staphylococcus aureus (MRSA) infections are challenging to treat. We compared antimicrobial activities in a rat model of chronic osteomyelitis in the context of retention of the foreign body without débridement. METHODS: MRSA was inoculated into the proximal tibia and a wire implanted. Four weeks after infection, treatment with vancomycin 50 mg/kg every 12 h, tigecycline 14 mg/kg every 12 h, rifampin 25 mg/kg every 12 h, or the combination of vancomycin or tigecycline plus rifampin was administered intraperitoneally for 21 days. RESULTS: MRSA was cultured from all tibias in the control group (median, 6.06 log10 CFU/g bone). Median bacterial counts (log10 CFU/g) at 48 h post-treatment were 6.16 for vancomycin (p = 0.753), 2.29 for vancomycin plus rifampin (p < 0.001), 5.90 for tigecycline (p = 0.270), 0.10 for tigecycline plus rifampin (p < 0.001), and 0.91 for rifampin (p = 0.044) treatment. Three deaths were observed in the tigecycline plus rifampin group. Median bacterial counts (log10 CFU/g) at two weeks post-treatment were 5.65 for vancomycin (p = 0.6), 4.05 for vancomycin plus rifampin (p = 0.105), 5.68 for tigecycline (p = 0.401), 4.05 for tigecycline plus rifampin (p = 0.028), and 5.98 for rifampin (p = 0.297) treatment. CONCLUSIONS: Tigecycline plus rifampin resulted in a significant bacterial count decrease, an effect more prominent at 48 h than two weeks after treatment completion. Tigecycline was not well tolerated at the dose studied.
OBJECTIVES: Implant-associated methicillin-resistant Staphylococcus aureus (MRSA) infections are challenging to treat. We compared antimicrobial activities in a rat model of chronic osteomyelitis in the context of retention of the foreign body without débridement. METHODS: MRSA was inoculated into the proximal tibia and a wire implanted. Four weeks after infection, treatment with vancomycin 50 mg/kg every 12 h, tigecycline 14 mg/kg every 12 h, rifampin 25 mg/kg every 12 h, or the combination of vancomycin or tigecycline plus rifampin was administered intraperitoneally for 21 days. RESULTS: MRSA was cultured from all tibias in the control group (median, 6.06 log10 CFU/g bone). Median bacterial counts (log10 CFU/g) at 48 h post-treatment were 6.16 for vancomycin (p = 0.753), 2.29 for vancomycin plus rifampin (p < 0.001), 5.90 for tigecycline (p = 0.270), 0.10 for tigecycline plus rifampin (p < 0.001), and 0.91 for rifampin (p = 0.044) treatment. Three deaths were observed in the tigecycline plus rifampin group. Median bacterial counts (log10 CFU/g) at two weeks post-treatment were 5.65 for vancomycin (p = 0.6), 4.05 for vancomycin plus rifampin (p = 0.105), 5.68 for tigecycline (p = 0.401), 4.05 for tigecycline plus rifampin (p = 0.028), and 5.98 for rifampin (p = 0.297) treatment. CONCLUSIONS:Tigecycline plus rifampin resulted in a significant bacterial count decrease, an effect more prominent at 48 h than two weeks after treatment completion. Tigecycline was not well tolerated at the dose studied.
Authors: Carlos J Sanchez; Stefanie M Shiels; David J Tennent; Sharanda K Hardy; Clinton K Murray; Joseph C Wenke Journal: Clin Orthop Relat Res Date: 2015-09 Impact factor: 4.176
Authors: Cassandra L Brinkman; Harmony L Tyner; Suzannah M Schmidt-Malan; Jayawant N Mandrekar; Robin Patel Journal: Antimicrob Agents Chemother Date: 2015-05-18 Impact factor: 5.191
Authors: Dina Elgazzar; Mohamed Aboubakr; Heba Bayoumi; Amany N Ibrahim; Safwa M Sorour; Mohamed El-Hewaity; Abulmaaty M Elsayed; Shaimaa A Shehata; Khaled A Bayoumi; Mohammed Alsieni; Maged Behery; Doaa Abdelrahaman; Samah F Ibrahim; Ahmed Abdeen Journal: Pharmaceuticals (Basel) Date: 2022-06-10
Authors: Rebecca A Garcia; David J Tennent; David Chang; Joseph C Wenke; Carlos J Sanchez Journal: Biomed Res Int Date: 2016-01-17 Impact factor: 3.411